742 related articles for article (PubMed ID: 26833257)
1. BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease.
Barão S; Moechars D; Lichtenthaler SF; De Strooper B
Trends Neurosci; 2016 Mar; 39(3):158-169. PubMed ID: 26833257
[TBL] [Abstract][Full Text] [Related]
2. The selective BACE1 inhibitor VIa reduces amyloid-β production in cell and mouse models of Alzheimer's disease.
Cheng X; Zhou Y; Gu W; Wu J; Nie A; Cheng J; Zhou J; Zhou W; Zhang Y
J Alzheimers Dis; 2013; 37(4):823-34. PubMed ID: 23948917
[TBL] [Abstract][Full Text] [Related]
3. BACE1 in Alzheimer's disease.
Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M
Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063
[TBL] [Abstract][Full Text] [Related]
4. Beta-secretase (BACE) as a drug target for Alzheimer's disease.
Vassar R
Adv Drug Deliv Rev; 2002 Dec; 54(12):1589-602. PubMed ID: 12453676
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of BACE1 Activity by a DNA Aptamer in an Alzheimer's Disease Cell Model.
Liang H; Shi Y; Kou Z; Peng Y; Chen W; Li X; Li S; Wang Y; Wang F; Zhang X
PLoS One; 2015; 10(10):e0140733. PubMed ID: 26473367
[TBL] [Abstract][Full Text] [Related]
6. BACE1: the beta-secretase enzyme in Alzheimer's disease.
Vassar R
J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
[TBL] [Abstract][Full Text] [Related]
7. Lessons from a BACE1 inhibitor trial: off-site but not off base.
Lahiri DK; Maloney B; Long JM; Greig NH
Alzheimers Dement; 2014 Oct; 10(5 Suppl):S411-9. PubMed ID: 24530026
[TBL] [Abstract][Full Text] [Related]
8. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions.
Klaver DW; Wilce MC; Cui H; Hung AC; Gasperini R; Foa L; Small DH
Biol Chem; 2010 Aug; 391(8):849-59. PubMed ID: 20731541
[TBL] [Abstract][Full Text] [Related]
9. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice.
Shimshek DR; Jacobson LH; Kolly C; Zamurovic N; Balavenkatraman KK; Morawiec L; Kreutzer R; Schelle J; Jucker M; Bertschi B; Theil D; Heier A; Bigot K; Beltz K; Machauer R; Brzak I; Perrot L; Neumann U
Sci Rep; 2016 Feb; 6():21917. PubMed ID: 26912421
[TBL] [Abstract][Full Text] [Related]
11. The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
Vassar R
J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of BACE1 for therapeutic use in Alzheimer's disease.
Luo X; Yan R
Int J Clin Exp Pathol; 2010 Jul; 3(6):618-28. PubMed ID: 20661410
[TBL] [Abstract][Full Text] [Related]
13. [BACE1 inhibitors for the treatment of Alzheimer disease].
Tomita T
Nihon Rinsho; 2016 Mar; 74(3):427-31. PubMed ID: 27025081
[TBL] [Abstract][Full Text] [Related]
14. BACE2 degradation mediated by the macroautophagy-lysosome pathway.
Liu X; Wang Z; Wu Y; Wang J; Song W
Eur J Neurosci; 2013 Jun; 37(12):1970-7. PubMed ID: 23773066
[TBL] [Abstract][Full Text] [Related]
15. Development of BACE1 inhibitors for Alzheimer's disease.
Guo T; Hobbs DW
Curr Med Chem; 2006; 13(15):1811-29. PubMed ID: 16787223
[TBL] [Abstract][Full Text] [Related]
16. Ginsenoside Rg1 attenuates β-amyloid generation via suppressing PPARγ-regulated BACE1 activity in N2a-APP695 cells.
Chen LM; Lin ZY; Zhu YG; Lin N; Zhang J; Pan XD; Chen XC
Eur J Pharmacol; 2012 Jan; 675(1-3):15-21. PubMed ID: 22166376
[TBL] [Abstract][Full Text] [Related]
17. Polymethoxyflavones: Novel β-Secretase (BACE1) Inhibitors from Citrus Peels.
Youn K; Yu Y; Lee J; Jeong WS; Ho CT; Jun M
Nutrients; 2017 Sep; 9(9):. PubMed ID: 28869548
[TBL] [Abstract][Full Text] [Related]
18. New BACE1 Chimeric Peptide Inhibitors Selectively Prevent AβPP-β Cleavage Decreasing Amyloid-β Production and Accumulation in Alzheimer's Disease Models.
Resende R; Ferreira-Marques M; Moreira P; Coimbra JRM; Baptista SJ; Isidoro C; Salvador JAR; Dinis TCP; Pereira CF; Santos AE
J Alzheimers Dis; 2020; 76(4):1317-1337. PubMed ID: 32597812
[TBL] [Abstract][Full Text] [Related]
19. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
Moussa CE
Expert Opin Investig Drugs; 2017 Oct; 26(10):1131-1136. PubMed ID: 28817311
[TBL] [Abstract][Full Text] [Related]
20. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.
Sankaranarayanan S; Price EA; Wu G; Crouthamel MC; Shi XP; Tugusheva K; Tyler KX; Kahana J; Ellis J; Jin L; Steele T; Stachel S; Coburn C; Simon AJ
J Pharmacol Exp Ther; 2008 Mar; 324(3):957-69. PubMed ID: 18156464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
